866-997-4948(US-Canada Toll Free)

Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)

Published By :

Daedal Research

Published Date : Sep 2014

Category :

Therapeutic Area

No. of Pages : 66 Pages

Scope of the Report

The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)” provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Pfizer Inc, Merck & Co, Allergan Inc and Alcon (Division of Novartis) are profiled in the report. 

Countries Coverage

  • The US
  • Japan

Company Coverage

  • Pfizer Inc, 
  • Merck & Co, 
  • Allergan Inc and 
  • Alcon (Division of Novartis) 
Executive Summary

Glaucoma, the second most common cause of blindness worldwide is generally characterized by relatively high intraocular pressure (IOP) as a result of impaired drainage of fluid, known as aqueous humor, from the eye. Currently approved treatments for glaucoma include a number of pharmaceutical drugs, laser therapies and surgical procedures. Glaucoma treatment forms a significant portion of the overall eye care market. 

The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years. 

The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug. 

Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed.
Table of Content

1. Executive Summary

2. Glaucoma: A Major Cause of Vision Loss
2.1 Overview
Table 1: Diagram of the Structure of the Eye (left) and Damage from Glaucoma (Right)
2.2 Types of Glaucoma
2.3 Prevention and Treatment of Glaucoma

3. Global Eye Care Market: An Analysis
3.1 Market Size
Table 2: Global Eye Care Market Size in US$ Billion, 2013-2018F
3.2 Market Segments
Table 3: Global Eye Care Market Segmentation in %, 2013
3.3 Surgical Market
Table 4: Breakup of Global Eye Surgical Market in US$ Billion, 2013
3.4 Ophthalmic Pharmaceuticals Market
Table 5: Breakup of Global Ophthalmic Pharmaceuticals Market in US$ Billion, 2013
3.5 Vision Care Market
Table 6: Breakup of Global Vision Care Industry in US$ Billion, 2013

4. Global Glaucoma Treatment Market: An Analysis
4.1 Market Size
Table 7: Global Glaucoma Treatment Market Sales in US$ Billion, 2010-2013
Table 8: Total Worldwide Glaucoma Market Annual Prescriptions in Million, 2012-2019F
Table A: Commonly Used Glaucoma Medications with Generic Equivalents
Table 9: Forecast Global Glaucoma Treatment Market in US$ Billion, 2014F-2019F
4.2 Share by Type of Drugs
Table 10: Market Share of Commonly Prescribed Glaucoma Drugs in %, 2013
4.3 Glaucoma Devices Market
Table 11: Global Glaucoma Devices Market Size in US$ Million, 2008-2013
Table 12: Global Glaucoma Devices Market Segmentation in %, 2013

5. Regional Analysis: Glaucoma Treatment Market
5.1 The US
Table 13: The US Glaucoma Market Sales in US$ Billion, 2012-2020F
Table 14: The US Glaucoma Market Annual Prescriptions in Million, 2012-2020F
Table 15: The US Glaucoma Market Composition in %, 2013
Table 16: The US Prostaglandin Market Sales and Annual Prescriptions, 2012-2020F
Table B: The US – Xalatan (latanoprost) Estimated Glaucoma Market, 2012-2020F
Table C: The US - Lumigan (bimatoprost) Estimated Glaucoma Market (AGN), 2012-2020F
Table D: The US – Travatan (travoprost) Estimated Glaucoma Market, 2012-2020F
Table E: The US – Zioptan Estimated Glaucoma Market, 2012-2020F
Table 17: The US Beta Blocker Market Sales and Annual Prescriptions, 2012-2020F
Table 18: The US Combination Glaucoma Market Sales and Annual Prescriptions, 2012-2020F
Table F: The US - Combigan Estimated Glaucoma Market (AGN), 2012-2020F
Table G: The US - Cosopt Estimated Glaucoma Market (AGN), 2012-2020F
Table H: The US - Simbrinza Estimated Glaucoma Market (NVS/Alcon), 2013-2020F
Table 19: The US Carbonic Anhydrase Market Sales and Annual Prescriptions, 2012-2020F
Table I: The US – Carbonic Anhydrase Inhibitors (Branded) Estimated Glaucoma Market, 2012-2020F
Table J: The US – Carbonic Anhydrase Inhibitors (Generics) Estimated Glaucoma Market, 2012-2020F
5.2 Japan
Table 20: Japan Prescription Ophthalmic Pharmaceuticals Market in US$ Billion, 2009-2013
Table 21: Japan Prescription Ophthalmic Pharmaceuticals Market Segmentation in %, 2013
Table 22: Japan Glaucoma Treatment Market in US$ Million, 2012-2013

6. Market Dynamics: Global Glaucoma Treatment Market
6.1 Growth Drivers
6.1.1 Rising Ageing Population
Table 23: Global Total Population ages 65 and above in Million, 2007-2013
6.1.2 Rising Healthcare Expenditures
Table 24: Global Healthcare Expenditures Per Capita in US$, 2007-2013
6.1.3 New Glaucoma Drug Delivery Devices
6.2 Key Issues
6.2.1 Strict Regulation and Marketing Approval
6.2.2 Long Product Development Process
6.2.3 Side Effects of Glaucoma Medications
6.3 Market Trends
6.3.1 Medicare Coverage of Glaucoma Patients
6.3.2 New Laser Technologies
6.3.3 Demand for Combination Glaucoma Drugs
Table 25: Share of Monotherapies and Combinations Glaucoma Drugs in %, 2013 versus 2018F

7. Competitive Landscape: Global Glaucoma Treatment Market
Table 26: Shares of Global Ophthalmic Laser Market Players in %, 2013

8. Company Profiles: Global Glaucoma Treatment Market
8.1 Pfizer Inc.
8.1.1 Business Description
Table 27: Pfizer’s Revenue Share by Business Segments in %, 2013
8.1.2 Financial Overview
Table 28: Pfizer – Revenues from Xalatan/Xalacom in US$ Million, 2011-2013
8.1.3 Business Strategies
8.2 Merck & Co., Inc.
8.2.1 Business Overview
Table 29: Merck & Co., Inc. Revenue by Business Segment in %, 2013
8.2.2 Financial Overview
Table 30: Merck & Co., Inc – Revenue from Cosopt/Trusopt in US$ Million, 2011-2013
8.2.3 Business Strategies
8.3 Allergan Inc.
8.3.1 Business Description
Table 31: Allergan Inc Business Segmentation by Revenue in %, 2013
8.3.2 Financial Overview
Table 32: Allergan – Revenue from Total Glaucoma Products in US$ Million, 2011-2013
8.3.3 Business Strategies
8.4 Alcon (Division of Novartis)
8.4.1 Business Description
8.4.2 Financial Overview
Table 33: Revenue from Alcon Division in US$ Million, 2011-2013
8.4.3 Business Strategies
Table K: Alcon - Ophthalmic Projects/Products Planned in Coming Years

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *